Incyte's INCA033989 Shows Promising Results in Myelofibrosis and Essential Thrombocythemia Trials

Event summary

  • Incyte presented updated Phase 1 data for INCA033989 at EHA 2026, showing rapid and sustained clinical and molecular responses in myelofibrosis (MF) and essential thrombocythemia (ET) patients.
  • INCA033989 demonstrated significant spleen volume reduction, symptom improvement, and anemia response in MF patients, with 55% achieving SVR25 and 39% achieving SVR35.
  • In ET patients, 70% achieved a complete hematologic response, with rapid and durable normalization of platelet counts.
  • The drug was well-tolerated, with 84% of MF patients and 95% of ET patients remaining on treatment.
  • Incyte plans to initiate a Phase 3 study for ET in mid-2026, following FDA Breakthrough Therapy designation.

The big picture

Incyte's INCA033989 represents a significant advancement in the treatment of myeloproliferative neoplasms, particularly for patients with CALR mutations who have limited therapeutic options. The positive Phase 1 data positions the drug as a potential game-changer in the oncology space, with the potential to modify disease progression. The upcoming Phase 3 study and regulatory engagement will be critical in determining the drug's commercial viability and market impact.

What we're watching

Regulatory Pathway
Whether the FDA Breakthrough Therapy designation will accelerate the approval process for INCA033989 in ET patients.
Clinical Development
The pace at which Incyte can initiate and complete the Phase 3 study for ET, given the positive Phase 1 data.
Market Potential
How INCA033989's targeted approach to CALR mutations could position it as a leading therapy for MPNs, addressing an unmet need in the market.

Related topics

Oncology